Manipal Health Enterprises IPO Review: India's Biggest Healthcare Listing Arrives at a Trimmed Valuation

Quick Answer

Manipal Health Enterprises IPO is India's largest healthcare public offering by issue size, and it is coming to market at a notably lower valuation than originally planned. The Bengaluru based hospital chain, backed by Temasek and Dr. Ranjan Pai's Manipal Education and Medical Group, opens for subscription on 29 July 2026 with a price band of Rs 560 to Rs 590, valuing the company at roughly Rs 77,607 crore at the upper end, well below an earlier planned valuation near Rs 1 lakh crore, a repricing that reporting has linked to cautious investor sentiment as Middle East tensions rattled global markets around the time of pricing. This is a genuinely large, established hospital network with real clinical scale, and roughly 60% of the money raised goes toward paying down debt at its main operating subsidiary rather than funding new hospitals.

Manipal Health Enterprises IPO Key Details at a Glance

What Does Manipal Health Enterprises Ltd Do?

Manipal Health Enterprises operates the Manipal Hospitals network, a pan-India chain of multispecialty hospitals delivering care across the full spectrum, from outpatient consultations to complex tertiary and quaternary interventions like organ transplants and advanced cardiac procedures. As of 31 March 2026, the company ran 49 hospitals with 13,037 licensed beds across 14 states and union territories, and per a CRISIL report cited in the offer documents, it has the widest footprint among private hospital chains in India by number of hospitals.

A genuinely distinctive competitive position. The company holds leadership positions in Karnataka, Maharashtra and Goa, and in Eastern India, and is the only private hospital chain leading three metro markets simultaneously by bed capacity, Bengaluru, Kolkata and Pune, a combination of dense metro coverage and non-metro reach that few competitors can match. You can follow its live price and post listing updates on the IPO GMP Live homepage.

The clinical infrastructure is genuinely top tier. The network served 6.30 million patients in FY26 on a pro forma basis, supported by over 11,000 doctors and a similar number of nurses, and equipped with 18 soft-tissue robots, 19 linear accelerators, 44 MRI scanners, 23 surgical robots and 58 catheterisation labs, infrastructure capable of supporting complex procedures including transplants, robotic surgery and interventional cardiology, not just routine hospital care.

Why Is the Valuation Lower Than Originally Planned?

Market conditions, not company performance, appear to be the driver. Business media reporting around the price band announcement noted the company opted for a lower valuation amid cautious investor sentiment toward large public offerings, as tensions in the Middle East, specifically around the Strait of Hormuz, added fresh turbulence to global markets in the weeks before pricing. Landing at roughly Rs 77,607 crore against an earlier reported target near Rs 1 lakh crore is a meaningful, publicly acknowledged repricing, and it is worth understanding as context for the valuation you would be buying into rather than assuming the number reflects a change in the underlying business.

How Strong Are Manipal Health Enterprises Financials?

Revenue and EBITDA have grown consistently and strongly across three years. Revenue rose from Rs 6,265 crore in FY24 to Rs 8,363 crore in FY25, up 33.5%, and to Rs 10,521 crore in FY26, up a further 25.8%. EBITDA followed an equally consistent path, from Rs 1,776.6 crore to Rs 2,247.07 crore (up 26.4%) to Rs 2,795.94 crore (up 24.4%), a genuinely healthy, sustained operating trend for a hospital chain this size.

Profit tells a more complicated story worth understanding rather than skipping past. Net profit surged 102.9% from Rs 533.20 crore in FY24 to Rs 1,081.67 crore in FY25, then fell 15.3% to Rs 916.52 crore in FY26, the year immediately before this listing. That decline sits oddly alongside continued strong revenue and EBITDA growth in the same year, suggesting the swing likely reflects one-off items, such as a gain recognised in FY25 or higher finance and tax costs in FY26, rather than the core hospital operations weakening. Investors should look for the company's own explanation of this specific profit pattern in the RHP's management discussion rather than assume it away.

These are standalone, not consolidated, financials, which matters for a holding company structure. Manipal Health Enterprises operates through material subsidiaries, including Manipal Hospitals Private Limited and step-down subsidiary Sahyadri Hospitals Private Limited, and the figures disclosed on this page are restated standalone numbers. For a group structured this way, the standalone financials may not fully capture the economics of the consolidated hospital network investors are actually gaining exposure to, worth keeping in mind when comparing this business to fully consolidated hospital chain peers.

Why Does Most of the Money Raised Go Toward Debt, Not New Hospitals?

The single largest use of proceeds is repaying debt at the main operating subsidiary. Of the Rs 9,275.22 crore raised, Rs 5,552.76 crore, roughly 60% of the entire issue, is earmarked for repaying or prepaying outstanding borrowings and accrued interest at Manipal Hospitals Private Limited, the company's material operating subsidiary. This is a substantial deleveraging exercise, consistent with a hospital network that has likely financed years of expansion and acquisitions, including the recent addition of hospitals that took the network from 38 to 49 facilities, partly through borrowed capital.

A further allocation buys out remaining minority shareholders in a key subsidiary. Rs 574 crore goes toward acquiring a minority stake in Sahyadri Hospitals Private Limited, a step-down subsidiary, consolidating full ownership of that business rather than sharing its economics with outside minority holders, a structurally sensible simplification for a company preparing to be a large, closely watched public entity.

This means only a modest share of the raise funds new growth directly. Unlike an IPO where most proceeds fund new hospital construction or bed expansion, this structure primarily strengthens the balance sheet and cleans up ownership at the subsidiary level, worth factoring into expectations about how directly this specific capital raise translates into near-term network expansion.

Should You Apply for the Manipal Health Enterprises IPO?

The issue opens on 29 July with a price band of Rs 560 to Rs 590. The honest read by investor type:

• Conservative investors: This is one of the more institutionally backed, scale-driven mainboard issues in recent memory, Temasek and Dr. Ranjan Pai's involvement, a genuinely global lead-manager syndicate, and real clinical infrastructure all support a reasonable long-term case. The valuation cut from the originally planned level is itself a point in favour of entering at a more conservative starting price than initially contemplated, though the FY26 profit decline and heavy debt-repayment use of proceeds deserve a closer look before applying.
• Moderate investors: The consistent revenue and EBITDA growth, market-leading position across three major metros, and advanced clinical capability make a credible long-term healthcare exposure case. Understanding the specific reason for the FY26 profit dip, and comparing standalone versus consolidated economics if that data becomes available, are worth doing before committing meaningful capital.
• Aggressive investors: As India's largest-ever healthcare IPO, this issue is likely to draw significant institutional and media attention through its subscription window, and the trimmed valuation could support a reasonable listing outcome if broader market sentiment stabilises. The Middle East-driven market caution that pressured the original valuation plan is the key external variable to watch between now and listing.

Honest take. Manipal Health Enterprises brings genuine scale and clinical credibility to the public markets, a market-leading hospital network with real infrastructure, consistent revenue and EBITDA growth, and blue-chip institutional backing. The valuation has already been trimmed once in response to market conditions, which is a point of reassurance for new investors relative to the company's original ambitions. The two things worth understanding clearly before applying are the FY26 profit decline despite strong revenue and EBITDA growth, which likely reflects one-off items but deserves the company's own explanation, and the fact that roughly 60% of this large raise goes toward debt repayment rather than funding new expansion directly.

Where Is the IPO Money Going?

Of the Rs 9,275.22 crore raised, the fresh issue portion of Rs 8,000 crore splits primarily between two uses: Rs 5,552.76 crore for repaying or prepaying outstanding borrowings and accrued interest at material subsidiary Manipal Hospitals Private Limited, and Rs 574 crore for acquiring a minority stake in step-down subsidiary Sahyadri Hospitals Private Limited. The remainder is allocated to general corporate purposes. The separate Rs 1,275.22 crore offer-for-sale portion goes entirely to selling shareholders, promoters Imperius Healthcare Investments Pte Ltd and Manipal Education and Medical Group India Private Limited, not to the company.

Contact Details

• Company: Manipal Health Enterprises Ltd.
• Location: Bengaluru, Karnataka
• Business: Pan-India multispecialty hospital network operating under the Manipal Hospitals brand, 49 hospitals across 14 states and union territories, offering outpatient through complex tertiary and quaternary care
• Promoters: Imperius Healthcare Investments Pte. Ltd. (Temasek), Manipal Education and Medical Group India Private Limited (Dr. Ranjan Pai)
• MD & CEO: Dilip Jose
• Registrar: KFin Technologies Ltd.
• Lead Managers: Kotak Mahindra Capital Co. Ltd., Axis Capital Ltd., Goldman Sachs (India) Securities Pvt. Ltd., Jefferies India Pvt. Ltd., JP Morgan India Pvt. Ltd., UBS Securities India Pvt. Ltd., DBS Bank India Ltd.
• Listing: BSE and NSE (Mainboard)

This page is not investment advice. GMP is indicative only and unofficial. Please consult a SEBI registered financial advisor before investing.